Co-Authors
This is a "connection" page, showing publications co-authored by AHMED KASEB and KHALED M ELSAYES.
Connection Strength
2.715
-
Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report. J Gastrointest Oncol. 2024 Jun 30; 15(3):1324-1330.
Score: 0.243
-
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2024 Jun 03; 29(6):e803-e810.
Score: 0.242
-
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. 2024; 41(1):83-91.
Score: 0.235
-
Multimodality annotated hepatocellular carcinoma data set including pre-?and post-TACE with imaging segmentation. Sci Data. 2023 01 18; 10(1):33.
Score: 0.220
-
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
Score: 0.218
-
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
Score: 0.200
-
Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma. 2020; 7:77-89.
Score: 0.182
-
Hepatocellular carcinoma response to transcatheter arterial chemoembolisation using automatically generated pre-therapeutic tumour volumes by a random forest-based segmentation protocol. Clin Radiol. 2019 Dec; 74(12):974.e13-974.e20.
Score: 0.174
-
Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study. J Comput Assist Tomogr. 2019 May/Jun; 43(3):499-506.
Score: 0.170
-
Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. Abdom Radiol (NY). 2018 12; 43(12):3340-3348.
Score: 0.165
-
Role of Wnt/?-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018; 5:61-73.
Score: 0.160
-
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016; 9:773-80.
Score: 0.136
-
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:1-7.
Score: 0.136
-
TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging. 2014 Oct; 39(5):1070-87.
Score: 0.124
-
A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell. 2019 Sep; 1(5).
Score: 0.044
-
Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol. 2017 Apr; 8(2):347-351.
Score: 0.037
-
Imaging features of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. 2014 Mar; 202(3):544-52.
Score: 0.030